Edition:
India

Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

3.31USD
18 Apr 2019
Change (% chg)

$0.01 (+0.30%)
Prev Close
$3.30
Open
$3.30
Day's High
$3.36
Day's Low
$3.21
Volume
27,360
Avg. Vol
69,638
52-wk High
$30.60
52-wk Low
$2.72

Latest Key Developments (Source: Significant Developments)

Advaxis Announces 1 For 15 Reverse Stock Split
Thursday, 28 Mar 2019 

March 28 (Reuters) - Advaxis Inc ::ADVAXIS ANNOUNCES REVERSE STOCK SPLIT.ANNOUNCES 1 FOR 15 REVERSE STOCK SPLIT.BEGINNING ON MARCH 29, 2019, ADVAXIS' COMMON STOCK WILL TRADE ON NASDAQ GLOBAL SELECT MARKET ON A REVERSE SPLIT-ADJUSTED BASIS.1-FOR-15 REVERSE STOCK SPLIT OF ITS COMMON STOCK WILL BECOME EFFECTIVE, MARCH 29, 2019.  Full Article

Advaxis Q3 Loss Per Share $0.27
Tuesday, 11 Sep 2018 

Sept 10 (Reuters) - Advaxis Inc ::ADVAXIS REPORTS FISCAL 2018 THIRD QUARTER BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS.QTRLY REVENUE $1.1 MILLION VERSUS $3.1 MILLION.Q3 LOSS PER SHARE $0.27.  Full Article

Advaxis Provides Update On MAA Filing And ADXS-Hot Program
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Advaxis Inc ::ADVAXIS PROVIDES UPDATE ON MAA FILING AND ADXS-HOT PROGRAM.ADVAXIS INC - CONTINUES TO BELIEVE THAT RESULTS FROM GOG-0265 STUDY ARE CLINICALLY MEANINGFUL.ADVAXIS - PLANS TO WITHDRAW CONDITIONAL MAA IN EUROPEAN UNION FOR AXALIMOGENE FILOLISBAC TO TREAT METASTATIC CERVICAL CANCER.ADVAXIS INC - CONTINUES TO BELIEVE AXALIMOGENE FILOLISBAC DEMONSTRATED CLINICAL ACTIVITY IN METASTATIC CERVICAL CANCER.ADVAXIS INC - HAS SUBMITTED AN IND WITH FDA TO STUDY ITS FIRST PRODUCT CANDIDATE FROM ADXS-HOT PROGRAM, ADXS-503, FOR TREATMENT OF NSCLC.ADVAXIS INC - REGULATORY ACTION IN EUROPE IS BASED ON EMA FEEDBACK FOLLOWING INITIAL REVIEW INDICATING APPLICATION WILL LIKELY NEED ADDITIONAL DATA.ADVAXIS INC - WITHDRAWAL OF MAA DOES NOT IMPACT ONGOING CLINICAL TRIALS OF AXALIMOGENE FILOLISBAC.ADVAXIS INC - EXPECTS FIRST PATIENT FOR ADXS-503, WILL BE DOSED BY END OF 2018.ADVAXIS INC - AFFIRMS PLANS TO SUBMIT A TOTAL OF FOUR INDS FOR DRUG CANDIDATES FROM ITS ADXS-HOT PROGRAM BY END OF CALENDAR YEAR 2019.ADVAXIS INC - ANTICIPATES SUBMITTING SECOND IND FROM ADXS-HOT PROGRAM WITHIN NEXT SIX MONTHS, FOR ITS DRUG ADXS-504 TO TREAT PROSTATE CANCER.  Full Article

Advaxis Reports Q1 Loss Per Share $0.49
Tuesday, 13 Mar 2018 

March 12 (Reuters) - Advaxis Inc ::ADVAXIS REPORTS FISCAL 2018 FIRST QUARTER FINANCIAL RESULTS AND ANNOUNCES CLINICAL HOLD IN AXALIMOGENE FILOLISBAC PHASE 1/2 COMBINATION STUDY WITH ASTRAZENECA’S IMFINZI® (DURVALUMAB).Q1 LOSS PER SHARE $0.49.Q1 EARNINGS PER SHARE VIEW $-0.55 -- THOMSON REUTERS I/B/E/S.ADVAXIS - FDA NOTIFIED IND FOR PHASE 1/2 COMBO STUDY OF AXALIMOGENE FILOLISBAC WITH IMFINZI FOR HPV-ASSOCIATED CANCERS WAS PLACED ON CLINICAL HOLD.CLINICAL HOLD PERTAINS TO RECENT SUBMISSION OF SAFETY REPORT TO FDA REGARDING GRADE 5 SERIOUS ADVERSE EVENT ON FEBRUARY 27.ADVAXIS - ENROLLMENT AND DOSING IN ALL OTHER ADVAXIS CLINICAL PROGRAMS ARE UNAFFECTED AT THIS TIME.ADVAXIS - "WE ARE CONFIDENT IN SAFETY AND EFFICACY PROFILE OF AXALIMOGENE FILOLISBAC, TO DATE".  Full Article

Advaxis Prices $20.0 Mln Public Offering Of Common Stock
Thursday, 22 Feb 2018 

Feb 22 (Reuters) - Advaxis Inc ::ADVAXIS PRICES $20.0 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 10.0 MILLION COMMON SHARES PRICED AT $2.00PER SHARE.  Full Article

Advaxis Expects To Report $59.4 Million Of Cash, Cash Equivalents And Investments As Of Jan 31
Thursday, 22 Feb 2018 

Feb 21 (Reuters) - Advaxis Inc ::ADVAXIS INC SAYS EXPECTS TO REPORT THAT IT HAD $59.4 MILLION OF CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JANUARY 31, 2018 - SEC FILING.  Full Article

Advaxis Announces Proposed Public Offering Of Common Stock
Thursday, 22 Feb 2018 

Feb 21 (Reuters) - Advaxis Inc ::ADVAXIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Advaxis Submits Conditional MAA For Second-Line Metastatic Cervical Cancer Treatment In European Union
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - Advaxis Inc ::ADVAXIS SUBMITS CONDITIONAL MARKETING AUTHORIZATION APPLICATION FOR AXALIMOGENE FILOLISBAC FOR THE SECOND-LINE TREATMENT OF METASTATIC CERVICAL CANCER IN EUROPEAN UNION.ADVAXIS INC - COMPANY WILL CONTINUE ASSESSING PARTNERSHIP OPPORTUNITIES FOR POTENTIAL COMMERCIALIZATION OF AXALIMOGENE FILOLISBAC IN EUROPE.ADVAXIS- DECIDED TO ALIGN, SIMPLIFY STRATEGY BY USING AXALIMOGENE FILOLISBAC EXCLUSIVELY IN ALL ONGOING AND PLANNED HPV-RELATED CANCER CLINICAL TRIALS.  Full Article

Aratana Therapeutics Granted Conditional License For A Canine Osteosarcoma Therapeutic
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Advaxis Inc ::ARATANA THERAPEUTICS GRANTED CONDITIONAL LICENSE FOR A CANINE OSTEOSARCOMA THERAPEUTIC.ARATANA THERAPEUTICS-U.S. DEPARTMENT OF AGRICULTURE CENTER FOR VETERINARY BIOLOGICS GRANTED CONDITIONAL LICENSE​ FOR CANINE OSTEOSARCOMA VACCINE,AT-014.  Full Article

Advaxis Q4 loss per share $1.74
Tuesday, 12 Sep 2017 

Sept 11 (Reuters) - Advaxis Inc :Advaxis reports business update and third quarter 2017 results.Q4 loss per share $1.74.  Full Article